title: Allosteric Inhibition of Factor XIIIa. Non-Saccharide Glycosaminoglycan Mimetics, but Not Glycosaminoglycans, Exhibit Promising Inhibition Profile.
abstract: Factor XIIIa (FXIIIa) is a transglutaminase that catalyzes the last step in the coagulation process. Orthostery is the only approach that has been exploited to design FXIIIa inhibitors. Yet, allosteric inhibition of FXIIIa is a paradigm that may offer a key advantage of controlled inhibition over orthosteric inhibition. Such an approach is likely to lead to novel FXIIIa inhibitors that do not carry bleeding risks. We reasoned that targeting a collection of basic amino acid residues distant from FXIIIa's active site by using sulfated glycosaminoglycans (GAGs) or non-saccharide GAG mimetics (NSGMs) would lead to the discovery of the first allosteric FXIIIa inhibitors. We tested a library of 22 variably sulfated GAGs and NSGMs against human FXIIIa to discover promising hits. Interestingly, although some GAGs bound to FXIIIa better than NSGMs, no GAG displayed any inhibition. An undecasulfated quercetin analog was found to inhibit FXIIIa with reasonable potency (efficacy of 98%). Michaelis-Menten kinetic studies revealed an allosteric mechanism of inhibition. Fluorescence studies confirmed close correspondence between binding affinity and inhibition potency, as expected for an allosteric process. The inhibitor was reversible and at least 9-fold- and 26-fold selective over two GAG-binding proteins factor Xa (efficacy of 71%) and thrombin, respectively, and at least 27-fold selective over a cysteine protease papain. The inhibitor also inhibited the FXIIIa-mediated polymerization of fibrin in vitro. Overall, our work presents the proof-of-principle that FXIIIa can be allosterically modulated by sulfated non-saccharide agents much smaller than GAGs, which should enable the design of selective and safe anticoagulants.
authors.affiliation: Department of Medicinal Chemistry & Institute for Structural Biology, Drug Discovery and Development, Virginia Commonwealth University, Richmond, Virginia, United States of America.
authors.forename: Rami A
authors.initials: RA
authors.lastname: Al-Horani
authors.affiliation: Department of Medicinal Chemistry & Institute for Structural Biology, Drug Discovery and Development, Virginia Commonwealth University, Richmond, Virginia, United States of America.
authors.forename: Rajesh
authors.initials: R
authors.lastname: Karuturi
authors.affiliation: Department of Medicinal Chemistry & Institute for Structural Biology, Drug Discovery and Development, Virginia Commonwealth University, Richmond, Virginia, United States of America.
authors.forename: Michael
authors.initials: M
authors.lastname: Lee
authors.affiliation: Department of Medicinal Chemistry & Institute for Structural Biology, Drug Discovery and Development, Virginia Commonwealth University, Richmond, Virginia, United States of America.
authors.forename: Daniel K
authors.initials: DK
authors.lastname: Afosah
authors.affiliation: Department of Medicinal Chemistry & Institute for Structural Biology, Drug Discovery and Development, Virginia Commonwealth University, Richmond, Virginia, United States of America.
authors.forename: Umesh R
authors.identifier: http://orcid.org/0000-0002-1976-6597
authors.initials: UR
authors.lastname: Desai
mesh_terms: D000494:Allosteric Regulation; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D026122:Factor XIIIa / Q000037:antagonists & inhibitors*; D005337:Fibrin / Q000737:chemistry; D006025:Glycosaminoglycans / Q000737:chemistry / Q000494:pharmacology*; D007700:Kinetics; D018716:Molecular Mimicry; D058105:Polymerization; D013329:Structure-Activity Relationship
chemical_list: D004791:Enzyme Inhibitors; D006025:Glycosaminoglycans; D005337:Fibrin; D026122:Factor XIIIa